
| 2015 | |
|---|---|
| Criterium: | Position: | 
| Overall Score: | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
| 2012 | |
| Criterium: | Position: | 
| Overall Score: | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
| 2011 | |
| Criterium: | Position: | 
| Overall Score: | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
| 2010 | |
| Criterium: | Position: | 
| Overall Score: | > 1000 | 
| Networking Rank (Reputation): | > 1000 | 
									Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2015 | 0 | 3.782.583 | 223.914 | 1 | ||
| 2013 | 0 | 3.971.184 | 173.823 | 1 | ||
| 2012 | 0 | 5.976.298 | 398.420 | 1 | ||
| 2011 | 0 | 3.740.034 | 211.419 | 1 | ||
| 2010 | 0 | 1.680.248 | 94.772 | 1 | ||
							Total number of partners: 50
							Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 47
Frequent / Rare Partner Ratio: 0.06
						
| Start date | Project | acronym | role | funding | partners | 
|---|---|---|---|---|---|
| 2015-01-01 | Chromatin Dynamics in Development and Disease | Chromatin3D | participant | 3.782.583 | 12 | 
| 2013-09-01 | Control of metabolic and inflammatory pathways by nuclear receptors | NR-NET | participant | 3.971.184 | 10 | 
| 2012-11-01 | "Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)" | TARGETAMD | participant | 5.976.298 | 15 | 
| 2011-11-01 | Transglutaminase in disease: a novel therapeutic target? | TRANSPATH | participant | 3.740.034 | 11 | 
| 2010-07-01 | The Commercialisation of Transglutaminase | TRANSCOM | participant | 1.680.248 | 7 |